Literature DB >> 29049083

Ketamine and pharmacological imaging: use of functional magnetic resonance imaging to evaluate mechanisms of action.

Eric A Maltbie1, Gopinath S Kaundinya, Leonard L Howell.   

Abstract

Ketamine has been used as a pharmacological model for schizophrenia as subanesthetic infusions have been shown to produce temporary schizophrenia-like symptoms in healthy humans. More recently, ketamine has emerged as a potential treatment for multiple psychiatric disorders, including treatment-resistant depression and suicidal ideation. However, the mechanisms underlying both the psychotomimetic and the therapeutic effects of ketamine remain poorly understood. This review provides an overview of what is known of the neural mechanisms underlying the effects of ketamine and details what functional MRI studies have yielded at a systems level focused on brain circuitry. Multiple analytic approaches show that ketamine exerts robust and consistent effects at the whole-brain level. These effects are highly conserved across human and nonhuman primates, validating the use of nonhuman primate models for further investigations with ketamine. Regional analysis of brain functional connectivity suggests that the therapeutic potential of ketamine may be derived from a strengthening of executive control circuitry, making it an intriguing candidate for the treatment of drug abuse. There are still important questions about the mechanism of action and the therapeutic potential of ketamine that can be addressed using appropriate functional neuroimaging techniques.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29049083      PMCID: PMC5687297          DOI: 10.1097/FBP.0000000000000354

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  125 in total

1.  Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs.

Authors:  Jesse Wood; Yunbok Kim; Bita Moghaddam
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

2.  Functional connectivity in frontal-striatal brain networks and cocaine self-administration in female rhesus monkeys.

Authors:  K S Murnane; K S Gopinath; E Maltbie; J B Daunais; Q K Telesford; L L Howell
Journal:  Psychopharmacology (Berl)       Date:  2014-08-21       Impact factor: 4.530

3.  A rating scale for psychotic symptoms (RSPS) part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations).

Authors:  G Chouinard; R Miller
Journal:  Schizophr Res       Date:  1999-08-17       Impact factor: 4.939

Review 4.  Risperidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Sandra Schwarz; Franziska Schmid; Heike Hunger; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

5.  Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers.

Authors:  S De Simoni; A J Schwarz; O G O'Daly; A F Marquand; C Brittain; C Gonzales; S Stephenson; S C R Williams; M A Mehta
Journal:  Neuroimage       Date:  2012-09-23       Impact factor: 6.556

6.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

7.  Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine.

Authors:  B Adams; B Moghaddam
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

8.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia.

Authors:  Alan Anticevic; Philip R Corlett; Michael W Cole; Aleksandar Savic; Mark Gancsos; Yanqing Tang; Grega Repovs; John D Murray; Naomi R Driesen; Peter T Morgan; Ke Xu; Fei Wang; John H Krystal
Journal:  Biol Psychiatry       Date:  2014-07-31       Impact factor: 13.382

10.  Ketamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model.

Authors:  Eric Maltbie; Kaundinya Gopinath; Naoko Urushino; Doty Kempf; Leonard Howell
Journal:  Psychopharmacology (Berl)       Date:  2015-12-10       Impact factor: 4.530

View more
  7 in total

1.  Examining fMRI time-series entropy as a marker for brain E/I balance with pharmacological neuromodulation in a non-human primate translational model.

Authors:  Eric A Maltbie; Leonard H Howell; Phillip Z Sun; Robyn Miller; Kaundinya S Gopinath
Journal:  Neurosci Lett       Date:  2020-04-18       Impact factor: 3.046

2.  Early Developmental Trajectories of Functional Connectivity Along the Visual Pathways in Rhesus Monkeys.

Authors:  Z Kovacs-Balint; E Feczko; M Pincus; E Earl; O Miranda-Dominguez; B Howell; E Morin; E Maltbie; L Li; J Steele; M Styner; J Bachevalier; D Fair; M Sanchez
Journal:  Cereb Cortex       Date:  2019-07-22       Impact factor: 5.357

3.  Cerebellar-cortical dysconnectivity in resting-state associated with sensorimotor tasks in schizophrenia.

Authors:  Dae-Jin Kim; Alexandra B Moussa-Tooks; Amanda R Bolbecker; Deborah Apthorp; Sharlene D Newman; Brian F O'Donnell; William P Hetrick
Journal:  Hum Brain Mapp       Date:  2020-04-06       Impact factor: 5.038

4.  Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.

Authors:  Chuanjun Zhuo; Feng Ji; Hongjun Tian; Lina Wang; Feng Jia; Deguo Jiang; Ce Chen; Chunhua Zhou; Xiaodong Lin; Jingjing Zhu
Journal:  Brain Behav       Date:  2020-07-03       Impact factor: 2.708

5.  Effect of mGluR2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia.

Authors:  Daniel H Wolf; David Zheng; Christian Kohler; Bruce I Turetsky; Kosha Ruparel; Theodore D Satterthwaite; Mark A Elliott; Mary E March; Alan J Cross; Mark A Smith; Stephen R Zukin; Ruben C Gur; Raquel E Gur
Journal:  Mol Psychiatry       Date:  2021-10-20       Impact factor: 13.437

6.  Pharmacological fMRI: Effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network.

Authors:  Felix Mueller; Francesco Musso; Markus London; Peter de Boer; Norman Zacharias; Georg Winterer
Journal:  Neuroimage Clin       Date:  2018-06-01       Impact factor: 4.881

7.  Adjunct ketamine treatment of depression in treatment-resistant schizophrenia patients is unsatisfactory in pilot and secondary follow-up studies.

Authors:  Chuanjun Zhuo; Xiaodong Lin; Hongjun Tian; Sha Liu; Haiman Bian; Ce Chen
Journal:  Brain Behav       Date:  2020-03-15       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.